屋尘螨变应原疫苗安脱达治疗过敏性哮喘457例的疗效及安全性分析

Effect and safety of immunotherapy with Alutard standardized mites allergens in 457 with allergic asthma

目的观察标准化屋尘螨变应原疫苗(安脱达,Alutard)特异性免疫疗法(SIT)治疗过敏性哮喘的疗效及安全性。方法比较457例对屋尘螨过敏的哮喘患者在接受3年免疫治疗前、后的疗效及免疫治疗过程中的局部和全身不良反应情况。结果治疗后过敏性哮喘患者的症状评分等多项指标均比治疗前有显著改善(P<0.05)。患者的应急用药量较治疗前明显减少(P<0.05)。治疗期间未发生严重不良事件。结论安脱达免疫治疗是一种安全、有效的治疗方法。

Objective To evaluate the safety and the effects of sublingual immunity therapy （SIT） with Alutard on dust mites related allergic asthma. Methods Comparison of the effect of 3 years immunotherapy before and after treatment and the local and systemic adverse reactions during immunotherapy were performed in 457 cases of dust mites related allergic asthma. Results After the treatment, many index of the patients were improved significantly （ P 〈 0.05 ）. The dosage for emergency treatment was reduced significantly （ P 〈 0.05）. No seriously adverse events happened during the whole treatment. Conclusion Immunotherapy with Alutard is an effective and safe method for dust mites allergic asthma.